{"id":"finacea","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Application site pain","drugRate":"6.2%","severity":"common","organSystem":""},{"effect":"Application site pruritus","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Application site dryness","drugRate":"0.7%","severity":"common","organSystem":""},{"effect":"Application site erythema","drugRate":"0.7%","severity":"common","organSystem":""}],"contraindications":["Skin hypopigmented","Skin irritation","Wilson's disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hypersensitivity","drugRate":"","severity":"serious"},{"effect":"Rash","drugRate":"","severity":"serious"},{"effect":"Worsening of asthma","drugRate":"","severity":"serious"},{"effect":"Hypopigmentation","drugRate":"","severity":"serious"},{"effect":"Eye and mucous membranes irritation","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Finacea® (azelaic acid) Gel, 15% (Intendis)"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Finacea","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:50:35.567487+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:50:41.109343+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Finacea","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:50:41.496732+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1238/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:42.280076+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"9fabd24e-4c3b-49a0-aa5f-c8d75ae67572","title":"FINACEA FOAM (AZELAIC ACID) AEROSOL, FOAM [LEO PHARMA INC.]"},"ecosystem":[],"mechanism":{"target":"3-oxo-5-alpha-steroid 4-dehydrogenase 2"},"_scrapedAt":"2026-03-27T23:31:56.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:43.837914+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Acne vulgaris","diseaseId":"acne-vulgaris","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rosacea","diseaseId":"rosacea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05416333","phase":"EARLY_PHASE1","title":"Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-08-12","conditions":"Central Centrifugal Cicatricial Alopecia","enrollment":18},{"nctId":"NCT06966388","phase":"PHASE1","title":"Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-08-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07327983","phase":"NA","title":"Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma","status":"COMPLETED","sponsor":"Gujranwala medical college District Headquarters Hospital, Gujranwala","startDate":"2025-05-04","conditions":"Melasma, Melasma (Facial Melasma)","enrollment":146},{"nctId":"NCT05446402","phase":"PHASE4","title":"Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2022-06-15","conditions":"Acne","enrollment":29},{"nctId":"NCT03094403","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-01","conditions":"Rosacea","enrollment":1000},{"nctId":"NCT00417937","phase":"PHASE4","title":"A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2007-01","conditions":"Papulopustular Rosacea","enrollment":98},{"nctId":"NCT00408330","phase":"PHASE2","title":"A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2006-12","conditions":"Seborrheic Dermatitis on the Face","enrollment":48},{"nctId":"NCT00403949","phase":"PHASE2","title":"A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2006-11","conditions":"Perioral Dermatitis","enrollment":48},{"nctId":"NCT00031096","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2002-01","conditions":"Acne Vulgaris","enrollment":879},{"nctId":"NCT01257919","phase":"PHASE1","title":"Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-01","conditions":"Papulopustular Rosacea","enrollment":21},{"nctId":"NCT01555463","phase":"PHASE3","title":"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-09","conditions":"Papulopustular Rosacea","enrollment":961},{"nctId":"NCT05887219","phase":"PHASE1","title":"Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma","status":"COMPLETED","sponsor":"Combined Military Hospital Abbottabad","startDate":"2022-11-01","conditions":"Melasma","enrollment":50},{"nctId":"NCT03826277","phase":"NA","title":"Efficacy of Melanostop Peeling for Improvement of Melasma","status":"UNKNOWN","sponsor":"VIST - Faculty of Applied Sciences","startDate":"2019-02-01","conditions":"Melasma","enrollment":10},{"nctId":"NCT01659853","phase":"PHASE3","title":"Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-09","conditions":"Erythema, Rosacea","enrollment":70},{"nctId":"NCT01139008","phase":"PHASE4","title":"Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-06","conditions":"Skin Manifestations","enrollment":80},{"nctId":"NCT01139047","phase":"PHASE4","title":"Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2010-06","conditions":"Skin Manifestations","enrollment":77},{"nctId":"NCT02800148","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2016-11","conditions":"Rosacea","enrollment":667},{"nctId":"NCT05014906","phase":"PHASE4","title":"Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea","status":"COMPLETED","sponsor":"Dermatology Specialists Research","startDate":"2010-05","conditions":"Rosacea","enrollment":60},{"nctId":"NCT04872946","phase":"NA","title":"Topical and Oral Regimen for Skin Health","status":"COMPLETED","sponsor":"Integrative Skin Science and Research","startDate":"2019-11-26","conditions":"Skin Abnormalities","enrollment":74},{"nctId":"NCT01494467","phase":"PHASE3","title":"Phase 3 Papulopustular Rosacea Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-12","conditions":"Papulopustular Rosacea","enrollment":688},{"nctId":"NCT01493687","phase":"PHASE3","title":"Phase 3 Papulopustular Rosacea Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-12","conditions":"Papulopustular Rosacea (PPR)","enrollment":683},{"nctId":"NCT02120924","phase":"PHASE3","title":"A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2013-07","conditions":"Rosacea","enrollment":1009},{"nctId":"NCT00617903","phase":"PHASE2","title":"Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-01","conditions":"Papulopustular Rosacea","enrollment":83},{"nctId":"NCT03193372","phase":"","title":"A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-07-20","conditions":"Rosacea","enrollment":2200},{"nctId":"NCT01430312","phase":"PHASE1","title":"21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT02602470","phase":"","title":"Preferences & Treatment Satisfaction Drivers in Rosacea Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01-08","conditions":"Rosacea","enrollment":206},{"nctId":"NCT01430533","phase":"PHASE1","title":"Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":240},{"nctId":"NCT00855595","phase":"PHASE4","title":"Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-02","conditions":"Papulopustular Rosacea","enrollment":207},{"nctId":"NCT01025635","phase":"PHASE2","title":"Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-12","conditions":"Papulopustular Rosacea","enrollment":401},{"nctId":"NCT03287791","phase":"PHASE3","title":"A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-07-19","conditions":"Rosacea","enrollment":924},{"nctId":"NCT03418610","phase":"PHASE4","title":"Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea","status":"COMPLETED","sponsor":"Clinical Research Center of the Carolinas","startDate":"2017-12-06","conditions":"Rosacea, Papulopustular","enrollment":5},{"nctId":"NCT03689010","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2017-12-12","conditions":"Rosacea","enrollment":1116},{"nctId":"NCT01631656","phase":"NA","title":"Combination Gel and Vascular ND in Mild to Moderate Rosacea","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2010-07","conditions":"Rosacea","enrollment":10},{"nctId":"NCT03035955","phase":"PHASE2, PHASE3","title":"Azelaic Acid on Demodex Counts in Rosacea","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2010-12","conditions":"Rosacea","enrollment":20},{"nctId":"NCT02058628","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-21","conditions":"Acne Vulgaris","enrollment":222},{"nctId":"NCT02147691","phase":"PHASE4","title":"Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2014-05","conditions":"Acne Rosacea","enrollment":22},{"nctId":"NCT01387048","phase":"PHASE4","title":"Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin","status":"COMPLETED","sponsor":"University of Magdeburg","startDate":"2011-08","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT01850095","phase":"NA","title":"The Influence of Peripheral Androgen Conversion at Women Adult Acne","status":"UNKNOWN","sponsor":"Marco Alexandre Dias da Rocha","startDate":"2012-03","conditions":"Acne, Quality of Life","enrollment":60},{"nctId":"NCT01038869","phase":"PHASE4","title":"Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2009-12","conditions":"Acne Vulgaris, Post Inflammatory Hyperpigmentation","enrollment":20},{"nctId":"NCT01180543","phase":"PHASE2","title":"Acne Treatment With Active Oplon's Patches","status":"COMPLETED","sponsor":"Oplon-Pure Science Ltd.","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT01260766","phase":"PHASE2","title":"Acne Treatment With Active Oplon's Patches - 15-18 Years Old","status":"UNKNOWN","sponsor":"Oplon-Pure Science Ltd.","startDate":"2011-01","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT01179633","phase":"PHASE1, PHASE2","title":"Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid","status":"COMPLETED","sponsor":"Oplon-Pure Science Ltd.","startDate":"2010-03","conditions":"Acne Vulgaris","enrollment":35},{"nctId":"NCT00848458","phase":"PHASE2, PHASE3","title":"Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2009-01","conditions":"Melasma","enrollment":70},{"nctId":"NCT00927771","phase":"PHASE4","title":"Azelaic Acid Versus Hydroquinone in Melasma","status":"UNKNOWN","sponsor":"Callender Center for Clinical Research","startDate":"2009-06","conditions":"Melanosis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":391,"reaction":"DRUG INEFFECTIVE"},{"count":359,"reaction":"PARAESTHESIA"},{"count":347,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":345,"reaction":"ABDOMINAL PAIN UPPER"},{"count":338,"reaction":"HYPOAESTHESIA"},{"count":325,"reaction":"BLEPHAROSPASM"},{"count":324,"reaction":"OFF LABEL USE"},{"count":322,"reaction":"PAIN"},{"count":316,"reaction":"EPILEPSY"},{"count":316,"reaction":"TASTE DISORDER"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1238"},"formularyStatus":[],"_approvalHistory":[{"date":"20150729","type":"ORIG","sponsor":"LEO PHARMA AS","applicationNumber":"NDA207071"},{"date":"20201201","type":"SUPPL","sponsor":"LEO PHARMA AS","applicationNumber":"NDA207071"},{"date":"20201201","type":"SUPPL","sponsor":"LEO PHARMA AS","applicationNumber":"NDA207071"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Dermatology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Finacea","genericName":"Finacea","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:43.837914+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}